Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer

Cancer, 10/21/2010

Docetaxel is the standard of care for patients with metastatic, castrate–resistant prostate cancer (CRPC). Gemcitabine is a nucleoside analogue with broad antitumor activity. In a phase 2 study of combined docetaxel and gemcitabine, the authors assessed its safety and activity in patients with chemotherapy–naive, metastatic CRPC. The efficacy of combined gemcitabine and docetaxel in metastatic CRPC was similar to that observed with single–agent docetaxel. In contrast to single–agent docetaxel, the combination was moderately toxic and had an impact primarily on bone marrow reserve.

Print Article Summary Cat 2 CME Report